{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T22:15:47Z","timestamp":1740176147743,"version":"3.37.3"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,11,25]],"date-time":"2019-11-25T00:00:00Z","timestamp":1574640000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,11,25]],"date-time":"2019-11-25T00:00:00Z","timestamp":1574640000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["JA Clin Rep"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Sodium-channel myotonia (SCM) is a nondystrophic myotonia, characterized by pure myotonia without muscle weakness or paramyotonia. The prevalence of skeletal muscle channelopathies is approximately 1 in 100,000, and the prevalence of SCM is much lower. To our knowledge, this is the first report on anesthetic management of a patient with SCM.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Case presentation<\/jats:title>\n<jats:p>A 23-year-old woman with congenital nasal dysplasia and SCM was scheduled to undergo rhinoplasty with autologous costal cartilage. Total intravenous anesthesia without muscle relaxants was administered followed by continuous intercostal nerve block. Although transient elevation of potassium level in the blood was observed during surgery, the patient did not show exacerbation of myotonic or paralytic symptoms in the postoperative period.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusion<\/jats:title>\n<jats:p>Total intravenous anesthesia and peripheral nerve block can be administered safely to a patient with SCM. However, careful monitoring of the symptoms and electrolytes is recommended.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s40981-019-0300-8","type":"journal-article","created":{"date-parts":[[2019,11,25]],"date-time":"2019-11-25T16:04:00Z","timestamp":1574697840000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Anesthetic management of a patient with sodium-channel myotonia: a case report"],"prefix":"10.1186","volume":"5","author":[{"given":"Naohisa","family":"Matsumoto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rei","family":"Nishimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6885-1982","authenticated-orcid":false,"given":"Yoshikazu","family":"Matsuoka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshimasa","family":"Takeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Morimatsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,11,25]]},"reference":[{"issue":"5","key":"300_CR1","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1097\/WCO.0b013e32833cc97e","volume":"23","author":"DL Raja Rayan","year":"2010","unstructured":"Raja Rayan DL, Hanna MG. Skeletal muscle channelopathies: nondystrophic myotonias and periodic paralysis. Curr Opin Neurol. 2010;23(5):466\u201376.","journal-title":"Curr Opin Neurol"},{"issue":"16","key":"300_CR2","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1212\/WNL.0b013e31828cf8d0","volume":"80","author":"A Horga","year":"2013","unstructured":"Horga A, Raja Rayan DL, Matthews E, Sud R, Fialho D, Durran SCM, et al. Prevalence study of genetically defined skeletal muscle channelopathies in England. Neurology. 2013;80(16):1472\u20135.","journal-title":"Neurology."},{"key":"300_CR3","first-page":"73","volume-title":"Myotonic dystrophy foundation toolkit","author":"N Campbell","year":"2015","unstructured":"Campbell N, Brandom B, Day JW, Moxley R. Practical suggestions for the anesthetic management of a myotonic dystrophy patient. In: Myotonic dystrophy foundation toolkit; 2015. p. 73\u201380."},{"issue":"9","key":"300_CR4","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1111\/pan.12120","volume":"23","author":"F Veyckemans","year":"2013","unstructured":"Veyckemans F, Scholtes JL. Myotonic dystrophies type 1 and 2: anesthetic care. Paediatr Anaesth. 2013;23(9):794\u2013803.","journal-title":"Paediatr Anaesth"},{"issue":"3","key":"300_CR5","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1093\/bja\/85.3.407","volume":"85","author":"M Bennun","year":"2000","unstructured":"Bennun M, Goldstein B, Finkelstein Y, Jedeikin R. Continuous propofol anaesthesia for patients with myotonic dystrophy. Br J Anaesth. 2000;85(3):407\u20139.","journal-title":"Br J Anaesth"},{"issue":"7","key":"300_CR6","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1097\/EJA.0000000000000442","volume":"33","author":"M Kosinova","year":"2016","unstructured":"Kosinova M, Stourac P, Harazim H, Janku P, Huser M, Vohanka S. Anaesthesia and orphan disease: rocuronium and sugammadex in the anaesthetic management of a parturient with Becker\u2019s myotonia congenita. Eur J Anaesthesiol. 2016;33(7):545\u20137.","journal-title":"Eur J Anaesthesiol"},{"issue":"5","key":"300_CR7","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1034\/j.1399-6576.2003.00116.x","volume":"47","author":"E Farbu","year":"2003","unstructured":"Farbu E, S\u00f8fteland E, Bindoff LA. Anaesthetic complications associated with myotonia congenita: case study and comparison with other myotonic disorders. Acta Anaesthesiol Scand. 2003;47(5):630\u20134.","journal-title":"Acta Anaesthesiol Scand"},{"issue":"4","key":"300_CR8","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1007\/s00540-007-0553-7","volume":"21","author":"T Kaneda","year":"2007","unstructured":"Kaneda T, Iwahashi M, Suzuki T. Anesthetic management for subtotal gastrectomy in a patient with paramyotonia congenita. J Anesth. 2007;21(4):500\u20133.","journal-title":"J Anesth"},{"issue":"4","key":"300_CR9","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1152\/advan.00121.2016","volume":"40","author":"BF Palmer","year":"2016","unstructured":"Palmer BF, Clegg DJ. Physiology and pathophysiology of potassium homeostasis. Adv Physiol Educ. 2016;40(4):480\u201390.","journal-title":"Adv Physiol Educ"},{"issue":"2","key":"300_CR10","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/S0006-3495(99)77249-8","volume":"76","author":"MP Takahashi","year":"1999","unstructured":"Takahashi MP, Cannon SC. Enhanced slow inactivation by V445M: a sodium channel mutation associated with myotonia. Biophys J. 1999;76(2):861\u20138.","journal-title":"Biophys J"},{"issue":"13","key":"300_CR11","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1001\/jama.2012.12607","volume":"308","author":"JM Statland","year":"2012","unstructured":"Statland JM, Bundy BN, Wang Y, Rayan DR, Trivedi JR, Sansone VA, et al. Mexiletine for symptoms and signs of myotonia in nondystrophic myotonia: a randomized controlled trial. JAMA. 2012;308(13):1357\u201365.","journal-title":"JAMA"},{"issue":"18","key":"300_CR12","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1212\/WNL.0b013e3181dc1a3a","volume":"74","author":"EL Logigian","year":"2010","unstructured":"Logigian EL, Martens WB, Moxley RT, McDermott MP, Dilek N, Wiegner AW, et al. Mexiletine is an effective antimyotonia treatment in myotonic dystrophy type 1. Neurology. 2010;74(18):1441\u20138.","journal-title":"Neurology"},{"issue":"Suppl 10","key":"300_CR13","first-page":"309","volume":"246","author":"SC Cannon","year":"2018","unstructured":"Cannon SC. Sodium channelopathies of skeletal muscle. Handb Exp Pharmacol. 2018;246(Suppl 10):309\u201330.","journal-title":"Handb Exp Pharmacol"},{"issue":"4","key":"300_CR14","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1213\/ane.0b013e3181a7c8e5","volume":"109","author":"J Parness","year":"2009","unstructured":"Parness J, Bandschapp O, Girard T. The myotonias and susceptibility to malignant hyperthermia. Anesth Analg. 2009;109(4):1054\u201364.","journal-title":"Anesth Analg"},{"issue":"3","key":"300_CR15","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1111\/j.1365-2044.2012.07075.x","volume":"67","author":"M Popat","year":"2012","unstructured":"Popat M, Mitchell V, Dravid R, Patel A, Swampillai C, Higgs A. Difficult Airway Society Guidelines for the management of tracheal extubation. Anaesthesia. 2012;67(3):318\u201340.","journal-title":"Anaesthesia"}],"container-title":["JA Clinical Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40981-019-0300-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s40981-019-0300-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40981-019-0300-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,24]],"date-time":"2020-11-24T00:04:44Z","timestamp":1606176284000},"score":1,"resource":{"primary":{"URL":"https:\/\/jaclinicalreports.springeropen.com\/articles\/10.1186\/s40981-019-0300-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,25]]},"references-count":15,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["300"],"URL":"https:\/\/doi.org\/10.1186\/s40981-019-0300-8","relation":{},"ISSN":["2363-9024"],"issn-type":[{"type":"electronic","value":"2363-9024"}],"subject":[],"published":{"date-parts":[[2019,11,25]]},"assertion":[{"value":"15 October 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 November 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient for publication of this case report.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"77"}}